Revenue
2018
2019
2020
2021
2022
2023
2024
2025
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $167.3M | $238.0M | $135.0M | $108.6M | $104.1M | $90.5M | $109.5M | $50.3M | $22.9M | $19.6M | $7.1M |
| Operating expenses | — | — | — | — | — | $136.6M | $146.0M | $78.4M | $32.4M | $25.9M | $10.6M |
| Operating income | −$192.0M | −$265.5M | −$184.4M | −$179.2M | −$170.1M | −$136.6M | −$146.0M | −$78.4M | −$32.4M | −$25.9M | −$10.6M |
| EBITDAderived | −$191.5M | −$264.8M | −$183.5M | −$178.3M | −$169.2M | −$135.9M | −$145.2M | −$78.0M | −$32.2M | −$25.8M | — |
| Net income | −$196.5M | −$260.6M | −$184.7M | −$181.1M | −$69.6M | −$134.0M | −$140.7M | −$74.1M | −$33.7M | −$25.9M | −$11.1M |
| Basic EPSper diluted share | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 | -$3.04 | -$3.86 | -$2.39 | -$2.83 | -$2.85 | -$1.18 |
| Diluted EPSper diluted share | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 | -$3.04 | -$3.86 | -$2.39 | -$2.83 | -$2.85 | -$1.18 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | TETRAULT LYNN A.Director | SellCommon Stock | 37.0K | $100.32 | $3.71M | 7.0K |
| May 15, 2026Form 4 | German Christopher PaulCorporate Controller & CAO | SellCommon Stock | 4.6K | $92.21 | $428.1K | 0 |
| Mar 4, 2026Form 4 | German Christopher PaulCorporate Controller & CAO | SellCommon Stock | 5.6K | $89.56 | $502.8K | 160 |
| Feb 19, 2026Form 4 · 10b5-1 | Smith Hunter CChief Financial Officer | SellCommon Stock | 585 | $103.28 | $60.4K | 110.5K |
| Feb 19, 2026Form 4 · 10b5-1 | Smith Hunter CChief Financial Officer | SellCommon Stock | 800 | $102.10 | $81.7K | 111.1K |